Q-omics provides the consensus-scored IGSF21 profile across patient tissues and cancer cell-line models. IGSF21 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IGSF21 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, IGSF21 RNA expression shows 17,193 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where IGSF21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGSF21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGSF21 survival associations across molecular data types. IGSF21 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGSF21 RNA expression–survival associations across cancer types. High IGSF21 expression shows unfavorable associations in OV, LUSC, STAD and BLCA, but favorable associations in SKCM and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IGSF21 RNA expression.
This table summarizes IGSF21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IGSF21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGSF21 shows lower tumor expression in BLCA and higher tumor expression in KIRC, THCA, HNSC, LIHC and CHOL. The KIRC box plot shows higher IGSF21 RNA expression in tumor versus normal tissue (log2 FC = +1.240, t-test p < 0.001).
This table shows molecular features associated with IGSF21 in patient tissues and cancer cell lines. In patient samples, IGSF21 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGSF21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
